Thomas Shelton, MD
Urology · Indianapolis, INNPI 1013449032
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (46.1%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 71.8% of it on its own, with 10 other manufacturers making up the rest. 2025 is the largest year on record at $3,574, 7.5 times the $479 reported in 2021.
Across 49 payments — averaging $109.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$4K
- Coloplast$381
- Richard Wolf Medical Instruments Corp.$334
- Dendreon Pharmaceuticals LLC$274
- Calyxo, Inc.$259
- Ambu Inc.$115
- plus $149 from 5 others
What the payments were for
- Consulting fees$4508%
- Speaking & faculty fees$2,47546%
- Travel & lodging$811%
- Food & beverage$2,33443%
- Education$351%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 17 | $3,861 |
| Coloplast | 16 | $381 |
| Richard Wolf Medical Instruments Corp. | 5 | $334 |
| Dendreon Pharmaceuticals LLC | 2 | $274 |
| Calyxo, Inc. | 2 | $259 |
| Ambu Inc. | 1 | $115 |
| Urogen Pharma, Inc. | 2 | $40 |
| AstraZeneca | 1 | $35 |
| Ferring Pharmaceuticals Inc. | 1 | $28 |
| Progenics Pharmaceuticals, Inc. | 1 | $26 |
| Endo Pharmaceuticals Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL KIDNEY STONE DISEASE$2,475
- GENERAL - THERAPIES$595
- PROVENGE$274
- CVAC Aspiration System$259
- LithoVue$143
- TITAN$134
How this compares
$5,374 in reported general payments places this provider in the 60th percentile of 272 urology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 31 | $16,873 |
| Potassium Citrate ErPotassium Citrate | 11 | $1,333 |
| Tamsulosin Hcl | 50 | $691 |
| Trospium Chloride | 21 | $486 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 21 | $236 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 29 | $94 |
| Diclofenac Sodium | 25 | $89 |
| Chlorthalidone | 12 | $83 |
| Cephalexin | 30 | $77 |
| Ciprofloxacin Hcl | 13 | $64 |
Paid to pharmacies, not to this prescriber.
Other urology in Indianapolis
- Michael BorofskyIndianapolis$244K
- Marcelino RiveraIndianapolis$171K
- Helen BernieIndianapolis$100K
- Austen SladeIndianapolis$73K
- Jacob RustIndianapolis$57K
- Alvin WeeIndianapolis$46K
- Jason SprungerIndianapolis$30K
- Steven KheyfetsIndianapolis$18K
- Hristos KaimakliotisIndianapolis$12K
- Adri DurantIndianapolis$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.